Pharmaceuticals

Rising cancer cases are fueling the Tumor Infiltrating Lymphocytes Market 2026

March 25, 2026March 25, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Tumor Infiltrating Lymphocytes Market By 2030 Starting From Its 2026 Size?

The tumor infiltrating lymphocytes market size has seen rapid growth in recent years. It is projected to expand from $12.05 billion in 2025 to $13.75 billion in 2026, registering a compound annual growth rate (CAGR) of 14.2%. This historical growth can be attributed to several factors, including the increasing prevalence of cancer, continuous advancements in immunotherapy research, a growing awareness of personalized medicine, the early successes observed with adoptive cell therapies, and strategic collaborations formed between research institutes and biotech companies.

The market size for tumor infiltrating lymphocytes is anticipated to undergo significant expansion in the coming years. It is projected to climb to $23.25 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.0%. This growth during the forecast period can be attributed to the rising acceptance of tumor infiltrating lymphocytes therapies, the proliferation of cGMP-compliant manufacturing facilities, the integration of AI in optimizing cell therapy processes, an increase in strategic alliances between pharmaceutical and biotechnology companies, and regulatory approvals for new T-cell therapies. Prominent trends for the forecast period include the evolution of personalized cell therapies, advanced ex vivo T-cell expansion methods, combination approaches in immunotherapy, modulation of the tumor microenvironment, and enhanced cell storage and cryopreservation techniques.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9440&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Tumor Infiltrating Lymphocytes Market?

The increasing prevalence of cancer patients is anticipated to boost the expansion of the tumor infiltrated lymphocytes (TIL) market moving forward. Cancer is defined as a condition where certain body cells multiply uncontrollably and spread to other areas, leading to various health issues, some of which can be life-threatening. Tumor-infiltrating lymphocytes are a specific type of immune cell with the ability to detect and eliminate cancer cells. These lymphocytes are extracted from a patient’s tumor, then cultivated in large quantities in a laboratory before being re-introduced into the patient to help their immune system destroy cancer cells. For instance, in August 2024, a report from the Australian Institute of Health and Welfare, a national Australian agency for health and welfare information, projected approximately 209,000 new cancer diagnoses in Australia by 2034. This represents a significant rise from the estimated 169,000 cases in 2024, reflecting the effects of population growth and increasing cancer rates. Additionally, in 2024, cancer is expected to be responsible for about 3 out of every 10 deaths in the country. Thus, the growth in cancer patients will propel the tumor infiltrated lymphocyte market.

Which Segment Categories Define The Tumor Infiltrating Lymphocytes Market?

The tumor infiltrating lymphocytes market covered in this report is segmented –

1) By Anatomy: CD3, CD8, CD16, CD56, CD4, CD57, FOXP3

2) By Component: T-Cells, Natural Killer Cells

3) By Application: Melanoma, Cervical Cancer, Ovarian Cancer, Other Applications

4) By End-User: Hospitals, Cancer Research Centers, Clinics

What Major Market Trends Are Driving Changes In The Tumor Infiltrating Lymphocytes Market?

Leading companies operating in the tumor-infiltrating lymphocyte market are increasingly adopting a strategic partnership approach, with the goal of developing innovative treatments that control gene editing. Strategic partnerships signify a process where companies utilize each other’s strengths and resources to achieve shared benefits and success. For instance, in February 2023, Moderna, a US-based pharmaceutical and biotechnology company, entered into a strategic collaboration with Life Edit Therapeutics, a US-based next-generation genome editing company, to accelerate the development of novel in vivo gene editing therapies. This partnership aims to leverage Moderna’s mRNA technology alongside Life Edit’s proprietary genome editing platform to create more effective and precise therapies for various diseases, including cancer and genetic disorders. The collaboration reflects an expanding trend within the biopharmaceutical industry to combine innovative technologies for advanced therapeutic solutions.

Who Are The Top Companies Competing In The Tumor Infiltrating Lymphocytes Market?

Major companies operating in the tumor infiltrating lymphocytes market are Novartis AG, Pfizer Inc., Precision BioScience Inc., TCR2 Therapeutics Inc., Merck KGaA, Autolus Therapeutics PLC., Eli Lilly and Company, Oxford Biomedica PLC., Unum Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., Sorrento Therapeutics Inc., TILT Biotherapeutics Ltd., Iovance Biotherapeutics Inc., Adaptimmune Therapeutics plc, Atara Biotherapeutics Inc., BioNTech SE, CARsgen Therapeutics Ltd., Cellectis S.A., Celyad Oncology SA, CRISPR Therapeutics AG, Intellia Therapeutics Inc., MaxCyte Inc.

Read the full tumor infiltrating lymphocytes market report here:

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Which Regions Are Projected To Dominate The Tumor Infiltrating Lymphocytes Market In The Coming Years?

North America was the largest region in the tumor infiltrating lymphocytes market in 2025. The regions covered in the tumor infiltrating lymphocytes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Tumor Infiltrating Lymphocytes Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9440&type=smp

Browse Through More Reports Similar to the Global Tumor Infiltrating Lymphocytes Market 2026, By The Business Research Company

Tumor Infiltrating Lymphocytes Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Cancer Immunotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Circulating Tumor Cells Market Report 2026

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795